ICU Medical (ICUI) shares plummeted 6.85% in Friday's pre-market trading, despite reporting better-than-expected second-quarter earnings. The medical device company's stock faced pressure as investors reacted to a narrowed full-year guidance range and a target price cut by Raymond James.
ICU Medical reported adjusted earnings of $2.10 per share for the quarter ended June 30, significantly surpassing the analysts' expectations of $1.50 per share. Revenue for the quarter came in at $543.6 million, slightly above the consensus estimate of $540.1 million. However, this represents a 6.4% decrease from the same period last year.
Despite the earnings beat, the company revised its full-year adjusted EPS guidance to a range of $6.85 to $7.15, compared to the previous outlook of $6.55 to $7.25. This narrowed range, coupled with Raymond James cutting its target price for ICU Medical from $187 to $180, appears to have overshadowed the positive quarterly results, leading to the sharp decline in stock price during pre-market trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。